Close menu




ASTRAZENECA PLC DL-_25

Photo credits: pixabay.com

Commented by Tarik Dede on August 17th, 2026 | 07:55 CEST

Cancer in Focus: Merck & Co., Vidac Pharma and AstraZeneca

  • Biotechnology
  • Biotech
  • Cancer
  • Innovations
  • Pharma
  • patents

According to the International Agency for Research on Cancer (IARC), part of the WHO, there are currently around 20.6 million new cancer cases worldwide. The annual death toll is estimated at approximately 10 million people. In recent years, more than 53 million people globally have received a cancer diagnosis. According to the WHO, the number of new cases per year is expected to rise to about 35 million by 2050. Two factors are generally cited as the main drivers: demographic change, with the global population getting older, as well as rising rates of obesity, physical inactivity, smoking and air pollution in many countries. Unsurprisingly, the oncology market is correspondingly lucrative. Oncology is the world's largest pharmaceutical market. There is, however, also some good news: the age-adjusted risk of dying from cancer is declining thanks to earlier detection, targeted therapies and advances in immuno-oncology. Today, we take a closer look at this market through the stocks of Merck & Co., Vidac Pharma and AstraZeneca.

Read

Commented by Nico Popp on September 18th, 2025 | 07:05 CEST

Understanding metabolism, generating returns: Vidac Pharma, Roche, AstraZeneca

  • Biotechnology
  • Biotech
  • Pharma
  • Innovations
  • Cancer

In the search for new treatments against diseases, researchers agree on one thing: the holy grail is unlikely to be found. Instead, it is incremental improvements and combination therapies that promise progress in complex diseases such as cancer. Cell metabolism is considered a promising approach, for example, in cancer, when the metabolism of a cancer cell is disrupted, the cell dies. In this article, we present current approaches and also discuss a biotechnology company that is wholly dedicated to cellular metabolism.

Read

Commented by Nico Popp on July 25th, 2025 | 07:00 CEST

Key technology in the fight against cancer? Merck & Co., Vidac Pharma, AstraZeneca

  • Biotechnology
  • Pharma
  • Cancer
  • Technology

Do you know what aerobic glycolysis is? No? Have you ever heard of the Warburg effect? Both terms describe the same phenomenon: cancer cells utilize glucose to produce lactate, even in the presence of oxygen and fully functional mitochondria. This is what distinguishes cancer cells from healthy cells. Current research suggests that targeted interventions in the Warburg effect could be suitable for killing cancer cells or making them more receptive to other therapies. Companies around the world are pushing forward research into this effect – the goal is nothing less than curing cancer. We present some of the companies and analyze whether their stocks could be good investments.

Read

Commented by André Will-Laudien on December 23rd, 2020 | 08:50 CET

Q & M Dental, Moderna, AstraZeneca: Serving people!

  • Health

Rarely has the stock market been so focused on people as it has been during the pandemic. People are thinking about which companies offer the best service package for all the problems associated with infections, vaccinations and even the psychological effects of isolation and loneliness. Humans are "social animals" with multiple social needs. Curtailing these needs works temporarily, but at some point, the arguments have to be genuinely purposeful so that certain restrictions continue to be accepted. At the peak of the contagion curve, we would like to see possible remedies that quickly turn the overall situation into a positive end - this is possible for the medium-term future. Still, in the short term, we have to stick together.

Read

Commented by Stefan Feulner on December 15th, 2020 | 15:37 CET

Moderna, AdTiger, AstraZeneca - here we go!

  • Investments

The announcement of the second lockdown last Sunday is a disaster for brick-and-mortar retailers. After an extremely sluggish Christmas season so far, the new closures will turn off the lights for stores during the most critical time of the year. Of the total 560,000 jobs in downtown retail, up to 250,000 are said to be acutely threatened. The beneficiary of this disastrous situation is once again, eCommerce. However, in addition to the major platforms Amazon, Alibaba or Zalando, other Internet companies are also profiting from the online trend.

Read